Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 4 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 28Parkinson Disease 4, Autosomal Dominant Lewy Body 4Neoplasms 3Neoplasm Metastasis 3Prostatic Neoplasms, Castration-Resistant 2Prostate Cancer Metastatic 2Metastatic Hormone Sensitive Prostate Cancer 2Metastatic Castration-resistant Prostate Cancer 2Bulbo-Spinal Atrophy, X-Linked 2mCRPC 1Recurrence 1Prostatic Diseases 1Patient Preference 1Metastatic Castration-resistent Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer 1MCRPC 1Genital Diseases, Male 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

enzalutamide 2cabazitaxel 2Prednisone 2Androgen Antagonists 2fludrocortisone acetate 1darolutamide 1XRP6258 1Radiosurgery 1Pluvicto 1Lutetium-177 1Lutetium 1Lenograstim 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Docetaxel 1Dexamethasone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Prostate Cancer Metastatic × enzalutamide × Clear all
NCT06136624 2026-05-05

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,310 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT03850795 2024-08-19

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Hinova Pharmaceuticals USA, Inc.

Phase 3 Terminated
104 enrolled
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡